Highland Capital Management (Tennessee)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,030	Closed	-$468K	–	360
2017 Q3	$468K	Buy	5,030 +55	+1%	+$4.86K	0.04%	272
2017 Q2	$452K	Buy	+4,975	New	+$453K	0.04%	282
2015 Q3	–	Sell	-300	Closed	-$41K	–	666
2015 Q2	$41K	Buy	+300	New	+$37.2K	﹤0.01%	404

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highland Capital Management (Tennessee)'s BMRN Position: Q4 2017 in Review

Highland Capital Management (Tennessee) sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 5,030 shares — an estimated $468K sold.

Highland Capital Management (Tennessee) first reported a position in BMRN in Q2 2015 and held it in 3 quarters. The position peaked at $468K in Q3 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

Highland Capital Management (Tennessee) reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Highland Capital Management (Tennessee) sold 5,030 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $468K.
Highland Capital Management (Tennessee) first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Highland Capital Management (Tennessee)'s BioMarin Pharmaceuticals position peaked at $468K in Q3 2017.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q4 2017, filed 26 Jan 2018.